share_log

Reported Saturday, Incyte Announced Results From Phase 3 POD1UM-303/InterAACT2 Trial Of Retifanlimab (Zynyz) In Combination With Platinum-based Chemotherapy (Carboplatin–Paclitaxel) For Inoperable Locally Recurrent Or Metastatic Squamous Cell Anal...

Benzinga ·  Sep 16 17:23

Reported Saturday, Incyte Announced Results From Phase 3 POD1UM-303/InterAACT2 Trial Of Retifanlimab (Zynyz) In Combination With Platinum-based Chemotherapy (Carboplatin–Paclitaxel) For Inoperable Locally Recurrent Or Metastatic Squamous Cell Anal Carcinoma

  • Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients with squamous cell anal carcinoma (SCAC) taking retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel)
  • Late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024 support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for retifanlimab in SCAC by year-end 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment